Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Gabor Marth, Mark Yandell, George Scangos


Gabor Marth and Mark Yandell are co-directors of the newly launched USTAR Center for Genetic Discovery, which will be housed at the University of Utah School of Medicine. The center will develop and commercialize computational methods for the discovery of relationships between genes and disease.

Marth, who will also serve as a professor of genetics at USTAR, was previously an associate professor of biology at Boston College. He holds a PhD from Washington University in St. Louis.

Yandell has been a faculty member at the University of Utah's Eccles Institute of Human Genetics since 2004. Prior to that, he was a senior scientist with Howard Hughes Medical Institute at the University of California, Berkeley. He holds a PhD from the University of Colorado, Boulder.

Agilent has appointed Biogen Idec CEO George Scangos to its board of directors, effective in September.

Prior to Biogen, Scangos served as president and CEO of Exelixis, a drug discovery and development company. He was previously president of Bayer Biotechnology.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.